The collaboration expands upon ContextVision's ongoing Data Quality initiative to develop AI-powered, organ-specific imaging solutions that enable MASLD screening and physiological quantification. The joint effort builds on ContextVision's strategic clinical partnership with the University of Washington (USA), where a clinical evaluation is underway to acquire imaging data for the development of a multiparameter biomarker for MASLD. AMRA Medical now joins this effort by adding their MRI-based analysis for measuring liver fat (PDFF), abdominal fat volumes, and detailed muscle assessment. AMRAs contribution will further enrich  the multimodal dataset by enabling correlations between MRI and ultrasound imaging biomarkers thereby strengthening ContextVision's development of disease staging solutions.

Combining strengths to advance liver diagnostics

"As we build out our Data Quality business, partnerships like this are essential," said Gerald Pötzsch, CEO of ContextVision. "AMRA's highly detailed MRI measurements, add critical value to our clinical data pipeline. Together, we are moving closer to a new standard in liver disease diagnostics - non-invasive, accurate, and scalable."

Olof Dahlqvist Leinhard, CEO of AMRA Medical, stated: "We're excited to join ContextVision's broader initiative to redefine liver diagnostics. Our combined technologies offer a more complete and individualized picture of patient health."

The collaboration supports ContextVision's growing list of global partners that already includes ultrasound imaging research from the University of Waterloo's LITMUS Lab (Canada) and R&D support from InPhase Solutions AS (Norway). Together, these partnerships underpin the expertise needed to discover and develop a robust, AI-powered diagnostic platform for MALD - grounded in imaging physics, clinical relevance, as well as high-quality multimodal data.

Meeting a global need for earlier, smarter liver diagnostics

MASLD affects approximately one in four people globally and is rapidly becoming one of the leading causes of chronic liver disease. The need for non-invasive, cost-effective diagnostic solutions is urgent - particularly as current methods often miss early stages of disease. By integrating MRI and ultrasound technologies through this partnership, ContextVision and AMRA Medical aim to deliver actionable, multimodal biomarkers to improve early detection and treatment planning for millions of patients.

For more information, please contact
Gerald Pötzsch
Chief Executive Officer, ContextVision
gerald.potzsch@contextvision.com

About ContextVision
ContextVision is a software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.